NYU Langone Health researchers have pinpointed how DNA copying failures at specific chromosome locations determine cancer cell sensitivity to PARP inhibitors, a discovery that shifts focus from damage quantity to genomic position for treatment efficacy.
Genetic Engineering & Biotechnology News reported that the study, published in Nature Cell Biology, identifies a subset of genomic sites, particularly near centromeres, where replication stress becomes lethal when a protective response is blocked by PARP inhibitors. The work, led by Eli Rothenberg, PhD, and Dipika Gupta, PhD, at NYU Perlmutter Cancer Center, used CRISPR screens and advanced imaging to reveal that the protein ESCO2 is a key determinant of this sensitivity, independent of the BRCA mutations typically targeted by these drugs.
Why Replication Fork Location Overrides Damage Quantity
For years, the prevailing model for PARP inhibitor efficacy has been rooted in the quantity of DNA damage. More damage, the theory went, meant a higher probability of killing a cancer cell. NYU’s research fundamentally challenges this assumption. The team’s quantitative single-molecule imaging, a technique developed in Rothenberg’s lab, allowed them to dissect replication stress with a resolution previously unattainable. This wasn’t just about counting breaks; it was about mapping their origin. “The imaging enabled us to move beyond measuring damage across an entire cell,” Gupta said. “We could detect subtle replication problems, distinguish the sites involved, and identify the protective response that the cells relied on.”
This protective response is a molecular triad. It hinges on PARP1 activity, supported by TIMELESS, which protects DNA replication forks, and DDX11, an enzyme capable of unwinding G-quadruplex (G4) structures. G4s are stable, four-stranded DNA folds that act as formidable roadblocks for the replication machinery. When ESCO2—a protein essential for holding newly duplicated chromosomes together—is depleted, these G4s proliferate, especially in the difficult-to-replicate pericentromeric regions. Normally, the TIMELESS-DDX11-PARP1 axis manages this. But block PARP, and the response collapses. G4s accumulate, DNA synthesis grinds to a halt, and the damage becomes catastrophic for the cell. The location of this failure, not the sheer number of lesions, is what dictates the cell’s fate.
ESCO2: The Unconventional Biomarker for Drug Response
The study’s findings introduce a new variable into the calculus of cancer treatment: ESCO2 expression. The research began with CRISPR screens in breast and small cell lung cancer models, which flagged ESCO2 as a strong predictor of PARP inhibitor sensitivity. The correlation held true even when the team tested other cancer types. Even a partial loss of ESCO2 function was enough to increase sensitivity in colorectal, ovarian, and lung cancer cells.
This sensitivity developed without damaging the homologous recombination (HR) pathway—the same process that fails in BRCA-mutated cancers, the usual targets for PARP inhibitors. This is a critical distinction. It suggests that a whole class of cancer patients, those without BRCA mutations but with low ESCO2 levels, might benefit from these drugs. The potential for a new biomarker is immense. Instead of sequencing for a specific gene, clinicians might one day assess ESCO2 protein levels or functional status to guide PARP inhibitor therapy. Rothenberg is already moving to translate this into the clinic, working with clinicians to apply the team’s imaging techniques to patient-derived cancer cells. The goal is to identify predictive patterns of replication stress and DNA damage.
The Genomic Achilles’ Heel: A New Target for Therapy?
The researchers describe their findings as revealing a “genomic Achilles’ heel”—a small subset of sites where replication problems trigger disproportionately severe consequences. These sites are the repetitive regions next to centromeres. These areas are notoriously difficult to replicate, prone to stalling and forming the problematic G4 structures.
This understanding opens new avenues for therapeutic intervention. If we know where the vulnerabilities are, can we design drugs that specifically target them? The study suggests that other DNA-damaging treatments might already be effective partly because they happen to hit these sensitive genomic hotspots. The implications for drug development are significant. “Our work reveals a genomic Achilles’ heel—a small subset of sites where replication problems can have disproportionately severe consequences. Identifying those sites helps explain what cancer cells depend on to survive and why a particular treatment can be so effective,” added Rothenberg. However, the study was conducted in cell models. Whether these features can reliably guide real-world treatment decisions requires further preclinical and clinical validation.
Cancer Drug Response Hinges on Damage Location
Cancer’s response to a leading class of drugs depends less on overall DNA damage and more on the precise location of that damage, a new study shows. Targeting a specific protein, ESCO2, could unlock PARP inhibitor therapies for a wider range of patients.
